Citigroup Inc. Reaffirms “Buy” Rating for GlaxoSmithKline plc (GSK)
Several other research analysts have also recently issued reports on the stock. BNP Paribas restated an underperform rating and issued a GBX 1,520 ($19.84) target price on shares of GlaxoSmithKline plc in a report on Friday, September 30th. JPMorgan Chase & Co. restated a neutral rating on shares of GlaxoSmithKline plc in a report on Thursday, September 22nd. Liberum Capital restated a buy rating and issued a GBX 1,900 ($24.80) target price on shares of GlaxoSmithKline plc in a report on Tuesday, September 20th. Goldman Sachs Group Inc. restated a buy rating and issued a GBX 1,800 ($23.50) target price on shares of GlaxoSmithKline plc in a report on Tuesday, September 20th. Finally, Beaufort Securities restated a buy rating on shares of GlaxoSmithKline plc in a report on Friday, September 16th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of GBX 1,682.13 ($21.96).
GlaxoSmithKline plc (LON:GSK) opened at 1717.00 on Wednesday. The stock’s market cap is GBX 83.46 billion. The firm has a 50-day moving average of GBX 1,645.03 and a 200-day moving average of GBX 1,551.57. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,718.50.
The company also recently announced a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Thursday, August 11th will be paid a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.12%. The ex-dividend date of this dividend is Thursday, August 11th.
In other news, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43). Also, insider Slaoui,Moncef bought 28 shares of GlaxoSmithKline plc stock in a transaction dated Friday, August 12th. The stock was purchased at an average price of GBX 2,208 ($28.82) per share, with a total value of £618.24 ($807.00).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.